ALSO Holding AG

Identity (GLEIF Global LEI Index)

Field	Value	Class
Legal name	ALSO Holding AG	SF
LEI	529900ACS8A6PTQI6141	SF
Swiss UID	CHE100000259	SF
Jurisdiction	CH	SF
Legal address	Meierhofstrasse 5, 6032, Emmen	SF
Headquarters	Meierhofstrasse 5, 6032, Emmen Emmen CH-LU	SF
Entity status	ACTIVE	SF
Geneva connection	none	CM

ⓘ

Listed securities (SIX Swiss Exchange issuer directory)

ISIN	Ticker	MIC	Share class	Segment	Accounting standard	Next GM	Auditor	Prov.
CH0024590272	ALSN	XSWX	Registered Share	International Reporting Standard	IFRS	not announced	PricewaterhouseCoopers AG - CH[500003]	ⓘ

Market snapshot

203.00 CHF
Stale — 11 days old · delayed per exchange agreement · yahoo

Metric	Value	Class
SMA 20	196.80	CM
SMA 50	187.09	CM
52-week range position	44% of range 133.40–292.50	CM
Trend (SMA20 vs SMA50)	up	CM
History depth	261 daily bars	SF

Analyst price targets

Low	Mean	Median	High	Analysts	Provider	As of
174.64091	214.17802	213.72897	258.11423	6	yahoo_analyst	2026-07-18T22:43:59Z

3 further data fields this platform tracks — no connected source covers this issuer yet. Shown to demonstrate capacity; each populates automatically when a source does, and nothing is estimated in the meantime. Show what is tracked ›

Financials (latest reported period)

Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.

No reported financial statements ingested for this company yet. Sources reach issuers progressively within their daily budgets: the keyed FMP weekly rotation (Mon income / Fri balance / Sat cash-flow families; US-listed free tier) plus — since 2026-07-07 — official filing-based paths: SEC XBRL company facts (US and 20-F/40-F cross-listed issuers with a resolved CIK) and filings.xbrl.org ESEF facts (EU/EEA issuers by LEI, where the national OAM shares). Figures are company disclosures — never estimated.

Recent company events

News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.

No company events ingested yet — the FMP rotation families (news, insider transactions, congressional disclosures, analyst estimates) populate this once a key is configured. Nothing is invented in the meantime.

Segment & geographic revenue (company disclosures)

Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.

No disclosed segment or geographic revenue ingested for this company yet. The Business Quant pipeline (SEC-parsed company disclosures) reaches US-listed issuers progressively within its daily budget; issuers that do not disclose segment detail keep this honest state.

How the company makes money

Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.

ALSO Holding AG or ALSO Group is a technology provider based in Emmen, Switzerland. ALSO is listed on the SIX Swiss Exchange under ticker ALSN.SW. The majority shareholder is the Droege Group. SF
source: wikipedia · retrieved 2026-07-19

Sector: wholesale peers

Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.

Corporate registry (OpenCorporates)

Official company-registry data aggregated by OpenCorporates; each value carries the registry's own snapshot date. Officers appear only where the registry publishes them (Swiss registries do not). The presence sweep lists same-name registrations across jurisdictions as labelled inference — never asserted subsidiaries.

Status: ACTIVE · Legal form: MVII · Registered address: Meierhofstrasse 5, 6032, Emmen · OC jurisdiction: CH · registry record ↗ · registry snapshot as of 2020-05-01

Registry presence sweep (1 candidate entities, Evidence-Based Inference — match basis recorded per row): ch (1)

Regulators of highest concern

Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.

Authority	Jur.	Matches	Max applicability	Max confidence
EU Publications Office (EU law)	EU	11	0.65	0.78
us_congress	US	7	0.65	0.68
SECO / WBF (Swiss sanctions & trade)	CH	1	0.65	0.78
General Services Administration	US	1	0.65	0.68
Commodity Futures Trading Commission	US	1	0.65	0.68

Regulatory exposure — matches with evidence

The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.

Rule	Instrument	Relationship	Applicability	Confidence	Exposure	Potential price impact (inference)	Review
R-SECTOR-MARKET_CONDUCT	Swiss Takeover Board: Beat Fellmann’s term of office extended by one year	sector_topic_candidate_market_conduct	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a Swiss market-conduct measure: if it applied it could raise conduct and compliance costs, or restrict certain market activities, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-MARKET_CONDUCT	Request for Comment on the Extension of Standard Futures Contracts to 24/7 Trading and on	sector_topic_candidate_market_conduct	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US market-conduct measure: if it applied it could raise conduct and compliance costs, or restrict certain market activities, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	General Services Acquisition Regulation; Acquisition of Information and Communication Tech	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1022R(01): Corrigendum to Commission Delegated Regulation (EU) 2026/1022 of 30	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1022: Commission Delegated Regulation (EU) 2026/1022 of 30 April 2026 amending	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1457: Commission Implementing Regulation (EU) 2026/1457 of 29 June 2026 on the	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1461: Regulation (EU) 2026/1461 of the European Parliament and of the Council	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1455: Regulation (EU) 2026/1455 of the European Parliament and of the Council	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1463: Council Regulation (EU) 2026/1463 of 25 June 2026 amending Regulation (E	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1465: Council Regulation (EU) 2026/1465 of 25 June 2026 amending Regulation (E	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1422: Commission Implementing Regulation (EU) 2026/1422 of 25 June 2026 amendi	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026R1540: Commission Implementing Regulation (EU) 2026/1540 of 6 July 2026 imposin	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	HR 9601 (119th Congress): To direct the United States Trade Representative to initiate inv	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	S 4883 (119th Congress): A bill to amend the Export Control Reform Act of 2018 to increase	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-MARKET_CONDUCT	HR 3402 (119th Congress): To amend the Securities Exchange Act of 1934 to require certain	sector_topic_candidate_market_conduct	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US market-conduct measure: if it applied it could raise conduct and compliance costs, or restrict certain market activities, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	S 4840 (119th Congress): Export Control Enforcement and Enhancement Act	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	HR 8169 (119th Congress): Export Control Enforcement and Enhancement Act	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	HR 4326 (119th Congress): To require the Congressional Budget Office to conduct an economi	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	HR 8770 (119th Congress): SAFEGUARDS Act of 2026	sector_topic_candidate_tariffs_trade_remedies	0.65	0.68	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-MARKET_CONDUCT	CELEX:32026R0788: Commission Delegated Regulation (EU) 2026/788 of 8 April 2026 amending D	sector_topic_candidate_market_conduct	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU market-conduct measure: if it applied it could raise conduct and compliance costs, or restrict certain market activities, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIES	CELEX:32026D1760: Political and Security Committee Decision (CFSP) 2026/1760 of 14 July 20	sector_topic_candidate_tariffs_trade_remedies	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review

Recent filings — potential impact inputs

A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.

No filings ingested yet. The authoritative filing venue for this issuer is SIX Exchange Regulation — issuer ad-hoc disclosures via SIX Swiss Exchange; an ingestion adapter for that venue is a tracked phased expansion. The gap stays visible — never padded.